Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07025577 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT07025577 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 82 participants.
The verdict
NCT07025577, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.
Interventions
- DRUG Immunoglobulin G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2025-06-02 |
| Est. Completion | 2025-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07025577
The ClinicalTrials.gov registry entry for NCT07025577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immunoglobulin G is the first listed.
NCT07025577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07025577 about?
NCT07025577 is a clinical study titled "A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions". This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.
What is the current status of trial NCT07025577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2025-06-02. Estimated completion is 2025-09-03.
What interventions are being tested in trial NCT07025577?
The interventions under investigation include: Immunoglobulin G (DRUG).
Who is sponsoring clinical trial NCT07025577?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.